Skip to main content
GastrointestinalSupplementsNutrition and dietMicrobiomeDietary supplement

What this study is

A single-arm, open-label prospective study will be conducted evaluating the impact of 8 weeks of supplementation at the manufacturer-recommended dose of Complete Commensal Probiotic™ on the GI-MAP stool test panel (Diagnostic Solutions Laboratory, Alpharetta, GA), gastrointestinal symptoms, digestion-associated quality of life. and overall physical health, mental health, and anxiety.

What's being tested

  • Complete Commensal Probiotic

    Intervention · DIETARY SUPPLEMENT

    Complete Commensal Probiotic™ contains five established commensal strains selected for their documented physiologic roles in the healthy adult gut. The five commensal strains in the product in this study are Akkermansia muciniphila (TA09), Bifidobacterium adolescentis (TA38), Bifidobacterium longum (TA24), Faecalibacterium prausnitzii (TA35), and Roseburia intestinalis (TA08).

Study details

Sponsor
OvationLab
Conditions
Gastrointestinal · Microbiota
Enrolling
25 people
Starts
2026-07-21
Est. completion
2026-11
Design
Open-label, single group
Record
View on ClinicalTrials.gov ↗